Highlights Almirall, S.A.

Equities

ALM

ES0157097017

Market Closed - BME Other stock markets 09:05:09 21/06/2024 pm IST			5-day change	1st Jan Change
9.62 ^EUR	-2.19%		-2.38%	+14.18%

10/06	Almirall: extension of indication in actinic keratosis	CF
10/06	Almirall’s Skin Disease Drug Gets US FDA Nod for Larger Treatment Area	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Almirall: extension of indication in actinic keratosis	10/06	CF
FDA Approves Almirall's Klisyri®? (Tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp Up to 100 Cm2	10/06	CI
Ex-dividend day for Cash amount paid with the scrip issue offered as an alternative to the dividend	17/05	FA
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	13/05
Almirall confirms full-year targets despite higher first-quarter costs	13/05	RE
Almirall: share price rises after 'solid' start to the year	13/05	CF
European shares listless as investors brace for inflation test	13/05	RE
Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024	13/05	CI
Almirall, S.A. Approves Distribution of Dividend	13/05	CI
Almirall, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	13/03	MT
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	19/02
Almirall: share price surges after agreement with Novo Nordisk	19/02	CF
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	19/02	MT
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	19/02	CI
Almirall, S.A. Provides Earnings Guidance for the Year 2024	19/02	CI
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	19/02	CI
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	21/12	CI
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies	12/12	MT
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology	12/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Almirall, S.A.

Equities

ALM

ES0157097017

Highlights

Filters